This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

POST-IT Clinical Registry Demonstrates Importance Of St. Jude Medical Fractional Flow Reserve Technology At EuroPCR 2014

Stocks in this article: STJ

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results from the POST-IT (Portuguese Study on the Evaluation of FFR Guided Treatment of Coronary Disease) registry were presented during a hot line late-breaking clinical trial session at EuroPCR 2014. Data from the registry, which was sponsored by the Portuguese Association of Cardiovascular Interventions, demonstrated that the use of St. Jude Medical PressureWire™ fractional flow reserve (FFR) technology changed the course of treatment for approximately half of the patients with coronary artery disease (CAD), thus ensuring patients with ischemia-producing narrowings received appropriate therapy.

“Data from the POST-IT registry provides further evidence of the benefits associated with FFR measurement technology in a real-world setting,” said Sergio B. Baptista, M.D., of Hospital Fernando Fonseca in Amadora, Portugal, a principal investigator of the POST-IT study. “The results demonstrate that FFR-guided therapy adds important information that alters the current treatment strategy within the cardiology community for PCI procedures, furthering my belief that FFR should become the standard of care for treating patients with coronary artery disease.”

POST-IT is a national, prospective, multi-center registry that enrolled 918 eligible patients at 19 centers in Portugal. Data from the registry highlighted the potential clinical and economic benefits of FFR measurement across a wide range of patients with both stable and unstable coronary artery disease. Results demonstrated that use of PressureWire FFR measurement systems results in improved treatment strategies for patients, with FFR changing the treatment strategy for more than 400 patients or 44.3 percent. Further, the registry found more patients were appropriate candidates for percutaneous coronary interventions (PCI) when assessed with FFR-guided therapy, increasing the number of patients referred for PCI from 35 percent to 43 percent.

“Collectively, these findings show that when FFR-guided therapy is used, cardiologists can significantly improve patient management,” said Luís F. Raposo, M.D., of Hospital de Santa Cruz in Carnaxide, Portugal, co-principal investigator of the POST-IT study. “The findings also suggest that FFR reduces costs to healthcare systems due, in part, to its ability to eliminate further non-invasive tests and potential future procedures.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs